Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array

Genes Chromosomes and Cancer

Volumn 45, Issue 11, 2006, Pages 1018-1032

  Liu, Wennuan ^a   Chang, Baoli ^a   Sauvageot, Jurga ^b   Dimitrov, Latchezar ^a   Gielzak, Marta ^b   Li, Tao ^a   Yan, Guifang ^b   Sun, Jishan ^a   Sun, Jielin ^a   Adams, Tamara S ^a   Turner, Aubrey R ^a   Kim, Jin Woo ^a   Meyers, Deborah A ^a   Zheng, Siqun Lilly ^a   Isaacs, William B ^b,d   Xu, Jianfeng ^a,c,d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d Marburg 115 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 21; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CONTENT; DNA COPY NUMBER; ERG GENE; GENE; GENE DELETION; GENE FUSION; GENE MAPPING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TMPRSS2 GENE;

AGED; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 33748924290     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20369     Document Type: Article

References (46)

1. Bova GS, Fox WM, Epstein JI. 1993. Methods of radical prostatectomy specimen processing: A novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 6:201-207.
2. Chu LW, Troncoso P, Johnston DA, Liang JC. 2003. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 36:303-312.
3. Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, Grassland S, Stratton MR, Wooster R, Campbell C, Cooper CS. 2003. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto c-DNA microarrays. Oncogene 22:1247-1252.
4. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. 2006. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet 38:75-81.
5. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. CaPSURE. 2003. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 170:S21-S25; discussion S26, S27.
6. Dong JT. 2001. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 20:173-193.
7. Dong JT. 2006. Prevalent mutations in prostate cancer. J Cell Biochem 97:433-447.
8. Dreher T, Zentgraf H, Abel U, Kappeier A, Michel MS, Bleyl U, Grobholz R. 2004. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444:509-517.
9. Dumur CI, Dechsukhum C, Ware JL, Cofield SS, Best AM, Wilkinson DS, Garrett CT, Ferreira-Gonzalez A. 2003. Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 81:260-269.
10. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
11. Gonzalgo ML, Isaacs WB. 2003. Molecular pathways to prostate cancer. J Urol 170:2444-2452.
12. Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA. 2006. Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet 38:82-85.
13. Huang J, Wei W, Zhang J, Liu G, Bignell GR, Stratton MR, Futreal PA, Wooster R, Jones KW, Shapero MH. 2004. Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics 1:287-299.
14. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C. 2004. Detection of large-scale variation in the human genome. Nat Genet 36:949-951.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. 2006. Cancer statistics, 2006. CA Cancer J Clin 56:106-130.
16. Kasahara K, Taguchi T, Yamasaki I, Kamada M, Shuin T. 2005. Genetic changes in localized prostate cancer of Japanese patients shown by comparative genomic hybridization. Cancer Genet Cytogenet 159:84-88.
17. Kibel AS, Faith DA, Bova GS, Isaacs WB. 2000. Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol 164:192-196.
18. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK. SanGiovanni JP. Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308:385-389.
19. Lieberfarb ME, Lin M. Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. 2003. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63:4781-4785.
20. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. 2004. dChipSNP: Significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20:1233-1240.
21. Liu W, Chang B, Li T, Dimitrov L, Kim S, Kim JW, Turner AR, Meyers DA, Trent JM, Zheng S, Isaacs WB, Xu J. Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects. Prostate (in press).
22. Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, West JA, Rostan S, Nguyen KC, Powers S, Ye KQ, Olshen A, Venkattaman E, Norton L, Wigler M. 2003. Representational oligonucleotide microarray analysis: A high-resolution method to detect genome copy number variation. Genome Res 13:2291-2305.
23. Majumder PK, Sellers WR. 2005. Akt-regulated pathways in prostate cancer. Oncogene 24:7465-7474.
24. McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, Dallaire S, Gabriel SB, Lee C, Daly MJ, Altshuler DM. International HapMap Consortium. 2006. Common deletion polymorphisms in the human genome. Nat Genet 38:86-92.
25. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. 1999. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291-4296.
26. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079.
27. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridly J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schroder FH, Vissers KJ, Watson VJ, Wildhagen MF, Collins C, Van Dekken H. 2003. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol 62:763-770.
28. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. 2004. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13:1303-1313.
29. Paris PL, Weinberg V, Simko J, Andaya A, Albo G, Rubin MA, Carroll PR, Collins C. 2005. Preliminary evaluation of prostate cancer metastatic risk biomarkers. Int J Biol Markers 20:141-145.
30. Postma R, van Marion R, van Duin M, Vissers KJ, Wink JC, Schroder FH, Tanke HJ, Szuhai K, van der Kwast TH, van Dekken H. 2006. Array-based genomic analysis of screen-detected Gleason score 6 and 7 prostatic adenocarcinomas. Anticancer Res 26:1193-1200.
31. Saramaki OR, Porkka KP, Vessella RL, Visakorpi T. 2006. Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer 119:1322-1329.
32. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. 2004. Large-scale copy number polymorphism in the human genome. Science 305:525-528.
33. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, Clark RA, Schwartz S, Segraves R, Oseroff VV, Albertson DG, Pinkel D, Eichler EE. 2005. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 77:78-88.
34. Slater HR, Bailey DK, Ren H, Cao M, Bell K, Nasioulas S, Henke R, Choo KH, Kennedy GC. 2005. High-resolution identification of chromosomal abnormalities using oligonucleotide arrays containing 116,204 SNPs. Am J Hum Genet 77:709-726.
35. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. 2006. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45:717-719.
36. Strohmeyer DM, Berger AP, Moore DH II, Bartsch G, Klocker H, Carroll PR, Loening SA, Jensen RH. 2004. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: Association with progression and angiogenesis. Prostate 59:43-58.
37. Teixeira MR, Ribeiro FR, Eknaes M, Waehre H, Stenwig AE, Giercksky KE, Heim S, Lothe RA. 2004. Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. Cancer 101:1786-1793.
38. Tomlins SA, Rhodes DR, Perner S. Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
39. Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, Haugen E, Hayden H, Albertson D, Pinkel D, Olson MV, Eichler EE. 2005. Fine-scale structural variation of the human genome. Nat Genet 37:727-732.
40. van Dekken H, Paris PL, Albertson DG, Alers JC, Andaya A, Kowbel D, van der Kwast TH, Pinkel D, Schroder FH, Vissers KJ, Wildhagen MF, Collins C. 2004. Evaluation of generic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39:249-256.
41. van Dekken H, Alers JC, Damen IA, Vissers KJ, Krijtenburg PJ, Hoedemaeker RF, Wildhagen MF, Hop WC, van der Kwast TH, Tanke HJ, Schroder FH. 2003. Genetic evaluation of localized prostate cancer in a cohort of forty patients: Gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 83:789-796.
42. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schroder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H. 2005. High-resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44:438-449.
43. Watson JE, Doggert NA, Albertson DG, Andaya A, Chinnaiyan A, van Dekken H, Ginzinger D, Ha C, James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, Simko JP, Volik S, Weinberg VK, Paris PL, Collins C. 2004. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23:3487-3494.
44. Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P, Allinen M, Elkahloun A, Monni O, Chen Y, Kallioniemi A, Kallioniemi OP. 2004. High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: Impact of copy number on gene expression. Neoplasia 6:240-247.
45. Yano S, Matsuyama H, Matsuda K, Matsumoto H, Yoshihiro S, Naito K. 2004. Accuracy of an array comparative genomic hybridization (CGH) technique in detecting DNA CN aberrations: Comparison with conventional CGH and loss of heterozygosity analysis in prostate cancer. Cancer Genet Cytogenet 150:122-127.
46. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Janne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M. 2005. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65:5561-5570.